乳腺癌是妇女常见恶性肿瘤.雌激素受体(ER)的发现使乳腺癌内分泌治疗效果有了明显的提高,尤其对ER阳性病例,有效率在50%以上;但ER阴性病例对内分泌冶疗多无反应,因此研究对ER阴性病人更有效的治疗方法甚为重要.原癌基因bcl-2的异常表达与肿瘤的发生和发展等密切相关,针对该基因设计的反义核酸药物已在人类淋巴瘤、小细胞肺癌、黑色素瘤以及前列腺癌等多种恶性肿瘤的治疗中显示了良好的应用前景.在乳腺癌中,大约50%以上的细胞过量表达bcl-2,应用反义核酸治疗乳腺癌,尤其ER阴性 Breast cancer is a common malignancy in women. The discovery of estrogen receptor (ER) has significantly improved the effect of endocrine therapy in breast cancer. Especially in ER-positive cases, the effective rate is more than 50%; however, ER-negative cases have endocrine therapy. There is no reaction, so it is very important to study a more effective treatment method for ER-negative patients. The abnormal expression of the oncogene bcl-2 is closely related to the occurrence and development of tumors. Antisense nucleic acid drugs designed for this gene have been used in humans. Therapeutic prospects for lymphoma, small cell lung cancer, melanoma, and prostate cancer have been shown to be promising. In breast cancer, approximately 50% of cells overexpress bcl-2 and use antisense nucleic acids to treat breast cancer. Cancer, especially ER negative